Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NUVB
- Price
- 1.99
- Stock movement up
- +0.24 (13.71%)
- Company name
- Nuvation Bio Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 667.78M
- Ent value
- 706.61M
- Price/Sales
- 248.24
- Price/Book
- 1.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -34.75%
- 3 year return
- -30.19%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NUVB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 248.24 |
| Price to Book | 1.33 |
| EV to Sales | 262.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 335.57M |
| EPS (TTM) | -1.95 |
| FCF per share (TTM) | -0.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.69M |
| Gross profit (TTM) | -793.00K |
| Operating income (TTM) | -134.45M |
| Net income (TTM) | -532.28M |
| EPS (TTM) | -1.95 |
| EPS (1y forward) | -0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -29.48% |
| Operating margin (TTM) | -4997.99% |
| Profit margin (TTM) | -19787.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.04M |
| Net receivables | 4.25M |
| Total current assets | 564.99M |
| Goodwill | 0.00 |
| Intangible assets | 2.78M |
| Property, plant and equipment | 0.00 |
| Total assets | 571.58M |
| Accounts payable | 12.38M |
| Short/Current long term debt | 11.19M |
| Total current liabilities | 59.03M |
| Total liabilities | 68.86M |
| Shareholder's equity | 502.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.03M |
| Capital expenditures (TTM) | 188.00K |
| Free cash flow (TTM) | -15.22M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -105.88% |
| Return on Assets | -93.12% |
| Return on Invested Capital | -103.42% |
| Cash Return on Invested Capital | -2.96% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.79 |
| Daily high | 2.03 |
| Daily low | 1.72 |
| Daily Volume | 4.18M |
| All-time high | 14.57 |
| 1y analyst estimate | 6.50 |
| Beta | 1.36 |
| EPS (TTM) | -1.95 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| NUVB | S&P500 | |
| Current price drop from All-time high | -86.34% | -12.89% |
| Highest price drop | -93.39% | -56.47% |
| Date of highest drop | 31 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -64.32% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 1022 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
667.78M
Marketcap category
Small-cap
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Employees
203
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page